Drug Combination Details
| General Information of the Combination (ID: C90308) | |||||
|---|---|---|---|---|---|
| Name | Yohimbine NP Info | + | Imipramine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hypertriglyceridaemia
[ICD-11: 5C80]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ADRA2A | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | HTR2C | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SSTR1 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Animals received yohimbine (2 mg/kg) 30 min prior to administration of imipramine(20 mg/kg) (Y + I group) or received vehicle treatment (Ctl group), once a day for seven consecutive days in adult male Wistar rats (250-400 g, 2-3 months of age) and adult male nestin-GFP transgenic mice (25-35 g, 2-3 months of age). | |||||
| Experimental
Result(s) |
Yohimbine and Imipramine combination treatment enhanced the quiescent neural progenitor pool in the hippocampal neurogenic niche similar to ECS, and distinct from chronic imipramine treatment. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Hippocampal transcriptional and neurogenic changes evoked by combination yohimbine and imipramine treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Aug 3;61:1-9. | |||
